fbpx

Novartis to Acquire Xiidra

Novartis announced that it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the assets associated with Xiidra® (lifitegrast ophthalmic solution) 5% worldwide. Xiidra is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease. The transaction would bolster the Novartis front-of-the-eye portfolio and ophthalmic leadership. Closing of the transaction is expected in second half of 2019, subject to customary closing conditions including regulatory approvals. On closing, Novartis plans a smooth transition of operations and integration of Xiidra into its pharmaceuticals portfolio.

Xiidra, with its anti-inflammatory mechanism of action, is the first dry eye treatment approved to treat both the signs of eye damage and the physical symptoms experienced by patients. Additional benefits of Xiidra, exhibited in phase III studies, include a timely onset of action and well-tolerated safety profile.

“Xiidra, with its unique dual benefits, is an example of the type of innovative advances we invest in for the benefit of patients,” said Paul Hudson, CEO Novartis Pharmaceuticals. “We look forward to leveraging our well-established commercial infrastructure to bring this medicine to more patients.”

In addition to powering Novartis’ ability to serve more patients suffering from eye disease, the additional commercial experience established with Xiidra is expected to better position the company for front-of-the-eye pipeline products currently in development.

Deal terms include a USD 3.4 billion upfront payment with potential milestone payments of up to USD 1.9 billion. As part of the agreement, Novartis will be taking on approximately 400 employees associated with the product.

Click HERE for the full press release.

Featured Posts

Trinity Capital Provides $45 Million Growth Capital To Neurolens

Trinity Capital Inc., a leading provider of diversified financial solutions to growth-stage companies, announced the commitment of $45 million in growth capital to Neurolens.

Learn More
OptikConED Year end special

Year-End Continuing Education Special: For Opticians and Optometric Assistants

From now until December 31, OptikConED.com offers year-end CE specials starting at $8.95 per course.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Read more

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

Trinity Capital Provides $45 Million Growth Capital To Neurolens

Trinity Capital Inc., a leading provider of diversified financial solutions to growth-stage companies, announced the commitment of $45 million in growth capital to Neurolens.

Learn More
OptikConED Year end special

Year-End Continuing Education Special: For Opticians and Optometric Assistants

From now until December 31, OptikConED.com offers year-end CE specials starting at $8.95 per course.

Read More

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Read More

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read More

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read More

Trinity Capital Provides $45 Million Growth Capital To Neurolens

Trinity Capital Inc., a leading provider of diversified financial solutions to growth-stage companies, announced the commitment of $45 million in growth capital to Neurolens.

Learn More
OptikConED Year end special

Year-End Continuing Education Special: For Opticians and Optometric Assistants

From now until December 31, OptikConED.com offers year-end CE specials starting at $8.95 per course.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Read more

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more

Trinity Capital Provides $45 Million Growth Capital To Neurolens

Trinity Capital Inc., a leading provider of diversified financial solutions to growth-stage companies, announced the commitment of $45 million in growth capital to Neurolens.

Learn More
OptikConED Year end special

Year-End Continuing Education Special: For Opticians and Optometric Assistants

From now until December 31, OptikConED.com offers year-end CE specials starting at $8.95 per course.

Read more

EssilorLuxottica and Moncler Announce Exclusive Licensing Agreement

EssilorLuxottica and Moncler have announced the signing of an exclusive licensing agreement that includes the design, production, and global distribution of Moncler eyewear.

Read more

OSI National Summit 2023: A Milestone Gathering Redefining the Future of Independent Optometry

Taking place at Toronto’s Westin Harbour Castle from November 17 to 19, the 2023 OSI National Summit brought together optometrists, opticians, optometric assistants, managers, and staff.

Read more

Diversity and Inclusion in Eye Care

Canada is an intricate textured tapestry of different cultures. Each patient is unique and presents with different preferences and lifestyle choices.

Read more